ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده: 3

Xenon Xe-129 hyperpolarized: Pediatric drug information

Xenon Xe-129 hyperpolarized: Pediatric drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Xenon Xe-129 hyperpolarized: Drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • Xenoview
Therapeutic Category
  • Radiopharmaceutical
Dosing: Pediatric
Diagnostic imaging

Diagnostic imaging:

Children ≥12 years and Adolescents: Oral inhalation: 75 to 100 mL Dose Equivalent (DE) via the entire contents of one dose delivery bag. Do not use dose delivery bag if the DE is <75 mL; DE of >100 mL is acceptable.

Note: DE is the total volume (mL) of 100% hyperpolarized, 100% isotopically enriched xenon Xe 129 that would provide the equivalent total Xe 129 magnetization (MRI) signal. DE is measured by the HPX Polarization Measurement Station and is defined by the following formula:

DE = (total volume xenon gas) × (fraction of xenon Xe 129 isotopic enrichment in the xenon gas) × (fraction of hyperpolarization)

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Adult

(For additional information see "Xenon Xe-129 hyperpolarized: Drug information")

Diagnostic imaging

Diagnostic imaging: Inhalation: Target dose: 75 to 100 mL dose equivalent (DE); minimum dose: 75 mL DE; >100 mL DE is acceptable. Administer DE in an appropriately sized dose delivery bag.

Dose delivery bag selection: Select the dose delivery bag based on the patient's total lung capacity (TLC) or forced vital capacity (FVC) (if TLC unavailable) (see table).

Recommended Dose Delivery Bag Volume Based on TLC or FVCa,b,c

TLC

FVCb

Dose delivery bag

a TLC = total lung capacity; FVC = forced vital capacity.

b FVC is used when TLC is unavailable.

c If both TLC and FVC are unavailable, select the dose delivery bag based on estimates of the patient's TLC using the American Thoracic Society-endorsed plethysmography-based predictive equations based on sex and height.

<2 L

<1.5 L

300 mL

2 to <3.3 L

1.5 to <2.5 L

500 mL

3.3 to <5 L

2.5 to <3.8 L

750 mL

≥5 L

≥3.8 L

1,000 mL

DE is the volume (mL) of 100% hyperpolarized, 100% isotopically enriched xenon XE 129 that produces the equivalent net magnetization as the Xe 129 dose and is defined by the following formula:

DE = (total volume xenon gas) × (fraction of xenon XE 129 isotopic enrichment in the xenon gas) × (fraction of hyperpolarization)

where volume of xenon gas is 250 to 750 mL, the fraction of xenon Xe 129 isotropic enrichment is >80% and the mean fraction of hyperpolarization is ≥38% to 54% at the completion of polarization of 250 mL of xenon gas.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.

1% to 10%:

Nervous system: Dizziness, headache

Respiratory: Oropharyngeal pain

Contraindications

There are no contraindications listed in the manufacturer's labeling.

Warnings/Precautions

Concerns related to adverse effects:

• Hypoxia: Transient hypoxemia may occur; treat as clinically indicated.

Other warnings/precautions:

• Appropriate use: Has not been evaluated for use with lung perfusion imaging. Concomitant supplemental oxygen may decrease image quality due to depolarization; withhold oxygen inhalation for 2 breaths prior to xenon Xe 129 hyperpolarized inhalation and resume immediately following imaging breath hold.

Warnings: Additional Pediatric Considerations

Transient heart rate elevation, numbness, and tingling have been reported with use in pediatric patients 6 to 18 years of age.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Gas, Inhalation:

Xenoview: 1% (1 ea)

Generic Equivalent Available: US

No

Pricing: US

Gas (Xenoview Inhalation)

1% (per each): $62,400.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Pediatric

Oral inhalation: Administer within 5 minutes of dose equivalent measurement; refer to the HPX Hyperpolarization System Operator's Manual and/or manufacturer labeling for detailed administration instructions.

Administration: Adult

Inhalation: Administer by inhalation within 5 minutes of dose equivalent measurement; refer to the HPX Hyperpolarization System Operator’s Manual and manufacturer labeling for detailed administration instructions.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F) for ≤5 minutes after final dose equivalent measurement; discard 60 minutes after filling dose delivery bag. Store xenon Xe 129 gas blend at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Use

Contrast agent for use with MRI for evaluation of lung ventilation (FDA approved in ages ≥12 years and adults). Note: Use in patients <12 years of age is not approved because the dose cannot be accurately administered.

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

Due to minimal absorption following inhalation, maternal use is not expected to result in fetal exposure.

Monitoring Parameters

Oxygen saturation; heart rate; signs or symptoms of hypoxemia.

Mechanism of Action

Contrast agent that when inhaled is distributed throughout the ventilated lung and can be used for imaging with a multi-nuclear capable MRI scanner; hyperpolarized xenon Xe 129 nuclei are directly detected by a Xe 129 MRI coil.

Pharmacokinetics (Adult Data Unless Noted)

Duration: Ventilated areas of the lungs; small amount into pulmonary vessels leading to distal organ distribution. Solubility is greater in fatty tissue than aqueous tissue or body compartments (eg, plasma).

Half-life elimination: 14.5 seconds (75% Xe/25% N2 gas mixture); 14.3 seconds (25% Xe/75% N2 gas mixture).

  1. Xenoview (xenon Xe 129 hyperpolarized) [prescribing information]. Durham, NC: Polarean Inc; May 2025.
Topic 140395 Version 16.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟